Skip to main content

An exceptional team with decades of experience at medical device start-ups and major corporations based in Switzerland and in California (USA)

CEO

Laurent Grandidier

Laurent is a global medtech executive with talent for turning research projects into commercially viable companies

Laurent leads the atHeart Medical team with over fifteen years of experience in medical device development and commercial leadership. He is a veteran in innovative cardiovascular devices and brings a solid track record of successfully building and leading diverse, cross functional teams for both start-ups and Fortune 500 companies, including Xeltis, Endosense, Boston Scientific, Guidant, and Procter and Gamble. Laurent holds several independent board positions and has received numerous professional awards including the 2018 Outstanding Executive at the Global Business Excellence Awards and the Best European CEO in Medical Devices by European CEO Magazine in 2015. He holds a Master of Science in Computer Science from the National Institute for Applied Sciences in Lyon, France, and an MBA from INSEAD, France-Singapore.
VP Quality

Maureen Bensing

Maureen’s expertise is setting up quality systems for successful start-up organizations.

Maureen is Vice-President of Quality for atHeart Medical since April 2022. She joined the company, bringing over twenty years of distinguished quality experience in multiple, prominent cardiovascular medical device start-ups such as Twelve and Ardian.

She has previously worked both in-house and as a consultant for a number of medical device companies that have been acquired by major medical device corporations, including Medtronic.

A biomedical engineer graduate from Marquette University in Milwaukee, WI, Maureen contributed to the development of intellectual property for systems and methods related to prosthetic heart valve devices.

In her spare time, she is also a Court Appointed Special Advocate (CASA) – volunteering to enrich the lives of kids in foster care.

VP Operations

Alexander Goehring

Alex’s broad range of expertise in operations and operations quality results from 30 years in the cardiac and cardiovascular medtech industry.

Alexander is Vice-President of Operations at atHeart Medical since May 2022. He has been with the company in a consulting role since it began operations in 2020.

With a drive for accomplishments and a strong compliance attitude, Alex has a remarkable experience spanning from manufacturing to clinical project management, from sales and business development to quality assurance.

Alex previously worked in-house at major corporations, such as Abbott and Guidant, and at start-up companies such as Xeltis. More recently, he also worked in the medtech industry as a consultant.

Alexander holds a biomedical engineering degree from Technical University Ulm, Germany.

VP R&D

Kuno Limacher

Kuno led the development of the reSept ASD Occluder with his expertise in engineering and cardiovascular device design.

Kuno leads the atHeart Medical product development team with twenty years of medical device engineering experience. His efforts and leadership have been instrumental in the development of the reSept ASD Occluder since the inception of the device in 2007. Kuno is co-author on several peer-reviewed publications and co-inventor on seven published patents. He holds a Bachelor of Science in Mechanical Engineering and a Master of Science in Industrial Management and Manufacturing, with a specialization in biocompatible materials and product management, from ETH Zurich, Switzerland.
VP R&D (NextGen)

Fabien Lombardi

Fabien’s successful track record in medical device development is the result of a forward-thinking mindset and strategic technical planning.

Fabien joined atHeart Medical as Vice President R&D in March 2023, leading the team driving forward the atHeart Medical R&D for next generation devices.

Fabien boasts a comprehensive 20-year background in project management, spanning across various facets from materials to the development of products. Prior to atHeart Medical, Fabien held leadership roles at startups in structural heart devices and biomaterials, including Symetis (acquired by Boston Scientific), Foldax (polymeric heart valve) and Open Stent Solutions (transcatheter mitral valve). In addition, Fabien’s career extended to well established companies such as Vascutek/Terumo and Datascope. His professional journey has taken him to multiple European countries, Australia and the United States.

A Mechanical Engineer graduate from University of Toulon, France and from University of West Scotland in Paisley, UK, Fabien gained his master’s degree in Polymer Science at University of North London, UK. He is main inventor or co-inventor of 15 patents granted between 2016 and 2022.

VP Clinical Affairs

Brandi Sadowski

Brandi is a seasoned clinical affairs leader with extensive experience building and executing successful clinical programs.

Brandi leads the atHeart Medical clinical affairs team with over twenty years of clinical affairs leadership experience. Her expertise includes overseeing global large-scale, multicenter randomized clinical trials, including both Investigational Device Exemption (IDE) and post-market studies. In addition to creating and implementing robust clinical programs, Brandi has played a key role in numerous regulatory submissions, strategic development, diligence, and fundraising efforts. Previously, she has held clinical leadership positions with innovative medical device companies such as EBR Systems, Cotera, Ivantis and Ardian. Brandi holds a Bachelor of Science in Genetics from the University of Wisconsin in Madison, WI.
VP Regulatory

Scott Wilson

Scott is a veteran regulatory affairs executive with a proven track record in successful global regulatory strategies.

Scott leads the atHeart Medical regulatory affairs team with over two decades of regulatory affairs leadership experience. His expertise includes developing and implementing global regulatory strategies including CE Marking, IDE, 510(k), PMA and de novo clearances. He has provided regulatory leadership for large-scale clinical studies and managed teams in executing international regulatory strategy expansions. Previously, he held senior regulatory roles with Cala Health, Twelve (MDT), Ardian (MDT), Radiant Medical and Edwards Lifesciences. Scott holds a Bachelor of Arts in Political Science and German from UC Berkeley and a PhD in Political Science from UC Santa Barbara.